Fabry nephropathy: a treatable cause of chronic kidney disease

Abstract

Fabry disease is a rare X-linked inborn error of metabolism that has a high prevalence of chronic kidney disease (CKD) and renal failure. It is due to the deficiency of the α-galactosidase A (α-Gal) lysosomal enzyme with subsequent accumulation of globotriaosylceramide (Gb3) in lysosomes. In the kidney, the podocyte is the main target of this disease, although all cell types are involved. The podocyte, being terminally differentiated, does not replicate and thus accumulates Gb3 throughout life. Podocytes are injured by Gb3, leading to their detachment from the glomerular basement membrane and subsequent loss in the urine. Albuminuria starts in childhood and progresses to overt proteinuria in the teens and 20 s. CKD ensues with adults starting dialysis at an average age of 42 years. Patients have a high prevalence of stroke and cardiomyopathy with hypertrophic change, heart failure, and dysrhythmias. Patient survival is limited in both genders. Diagnosis is based on the demonstration of a low α-Gal activity and a pathogenic GLA mutation. Clinical features are highly variable, which makes recognition of this condition difficult. Treatment with intravenous recombinant human enzyme replacement therapy (ERT) and oral pharmacologic chaperone are available. Control of proteinuria to 0.5 g/day or less is of critical importance to limit progression to end-stage renal disease. Early initiation of treatment gives the best results, but the optimal age to start is uncertain. Fabry nephropathy remains a challenge due to its multisystem nature, difficult diagnosis, and complicated management. It is important as a treatable cause of CKD.

Keywords

Rare disease / enzyme replacement therapy / pharmacologic chaperone / Fabry disease / Gb3 / lyso-Gb3

References

[1] Germain DP.Fabry disease.Orphanet J Rare Dis2010;5:30 PMCID:PMC3009617

[2] Thadhani R,West ML.Patients with Fabry disease on dialysis in the United States.Kidney Int2002;61:249-55

[3] Levey AS,Tsukamoto Y.Definition and classification of chronic kidney disease: a position statement from Kidney disease: improving global outcomes (KDIGO).Kidney Int2005;67:2089-100

[4] Meikle PJ,Clague AE.Prevalence of lysosomal storage disorders.JAMA1999;281:249-54

[5] Spada M,Yasuda M.High incidence of later-onset Fabry disease revealed by newborn screening.Am J Hum Genet2006;79:31-40 PMCID:PMC1474133

[6] Hwu WL,Lee NC.Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A).Hum Mutat2009;30:1397-405 PMCID:PMC2769558

[7] Lin HY,Hsu JH.High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population.Circ Cardiovasc Genet2009;2:450-6

[8] Kermond-Marino A,Xi Zhang SK,Huang M.Population frequency of undiagnosed Fabry disease in the general population.Kidney Int Rep2023;8:1373-9 PMCID:PMC10334396

[9] Sirrs S,Bichet DG.Baseline characteristics of patients enrolled in the Canadian Fabry disease initiative.Mol Genet Metab2010;99:367-73

[10] Branton MH,Sabnis SG.Natural history of Fabry renal disease: influence of alpha-galactosidase a activity and genetic mutations on clinical course.Medicine2002;81:122-38

[11] Ortiz A,Waldek S,Cianciaruso B.Fabry RegistryNephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.Nephrol Dial Transplant2008;23:1600-7

[12] Germain DP,Burlina A.Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: a multicenter Fabry registry study.Mol Genet Genom Med2018;6:492-503 PMCID:PMC6081232

[13] Oder D,Hu K.α-galactosidase a genotype N215S Induces a specific cardiac variant of Fabry disease.Circ Cardiovasc Genet2017;10:e001691

[14] Lavalle L,Beaton B.Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation.PLoS One2018;13:e0193550 PMCID:PMC5886405

[15] Hsu TR,Chang FP.Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4 + 919G > A).Orphanet J Rare Dis2014;9:96 PMCID:PMC4100491

[16] Lin HY,Yu HC.Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4 + 919G→A).J Inherit Metab Dis2010;33:619-24

[17] Lukas J,Eichler S.Functional and clinical consequences of novel α-galactosidase a mutations in Fabry disease.Hum Mutat2016;37:43-51

[18] Selvarajah M,Hewitson TD.Targeted urine microscopy in anderson-Fabry disease: a cheap, sensitive and specific diagnostic technique.Nephrol Dial Transplant2011;26:3195-202

[19] Fall B,Mauer M.Urinary podocyte loss is increased in patients with Fabry disease and correlates with clinical severity of Fabry nephropathy.PLoS One2016;11:e0168346 PMCID:PMC5161377

[20] Mignani R,Granata A.Isolated microalbuminuria as the first clinical presentation of Fabry disease in an adult heterozygous female.NDT Plus2009;2:455-7 PMCID:PMC4421328

[21] Marchel D,Larkina M.The significance of hematuria in podocytopathies.Clin J Am Soc Nephrol2023;19:56-66 PMCID:PMC10843204

[22] Pisani A,Pellegrino A.Parapelvic cysts, a distinguishing feature of renal Fabry disease.Nephrol Dial Transplant2018;33:318-23

[23] Wornell P,Crocker J,Acott P.Fabry disease and nephrogenic diabetes insipidus.Pediatr Nephrol2006;21:1185-8

[24] Sessa A,Battini G.Renal pathological changes in Fabry disease.J Inherit Metab Dis2001;24:66-70

[25] Schiffmann R,Banikazemi M.Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.Nephrol Dial Transplant2009;24:2102-11 PMCID:PMC2698092

[26] West M,Mehta A.Agalsidase alfa and kidney dysfunction in Fabry disease.J Am Soc Nephrol2009;20:1132-9 PMCID:PMC2678048

[27] Schwarting A,Feriozzi S,Mehta A.European FOS InvestigatorsEnzyme replacement therapy and renal function in 201 patients with Fabry disease.Clin Nephrol2006;66:77-84

[28] Wanner C,Jovanovic A.Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis.ESC Heart Fail2020;7:825-34 PMCID:PMC7261571

[29] Arends M,Hughes D.Characterization of classical and nonclassical Fabry disease: a multicenter study.J Am Soc Nephrol2017;28:1631-41 PMCID:PMC5407735

[30] Arends M,Hughes DA.Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors.PLoS One2017;12:e0182379 PMCID:PMC5538714

[31] Drechsler C,Niemann M.Potential role of vitamin D deficiency on Fabry cardiomyopathy.J Inherit Metab Dis2013;37:289-95 PMCID:PMC3976508

[32] Chiorean A,Kabadi S.Cluster analysis of kidney function decline among males with Fabry disease in a large United States electronic health records database.Nephrol Dial Transplant2023;38:2350-7 PMCID:PMC10539200

[33] Sharma A,Zaragoza JJ.Fabry’s disease: an example of cardiorenal syndrome type 5.Heart Fail Rev2015;20:689-708

[34] Siegenthaler M,Krayenbuehl P.Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up.Int J Cardiol2017;249:261-7

[35] Clements JN.Development and current role of sodium glucose cotransporter inhibition in cardiorenal metabolic syndrome.J Cardiovasc Pharmacol2022;79:593-604

[36] Bird S,Mehta A,Hughes D.Fabry disease and incidence of cancer.Orphanet J Rare Dis2017;12:150 PMCID:PMC5588622

[37] Pagni F,Zannella S.Possible pathogenetic relationship between Fabry disease and renal cell carcinoma.Am J Nephrol2012;36:537-41

[38] Linthorst GE,Aerts JM.Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers.Clin Chim Acta2005;353:201-3

[39] Ferreira S,Germain DP.The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies.Mol Genet Metab2015;114:248-258 PMCID:PMC4423738

[40] Cerón-Rodríguez M,Barajas-Colón E,Salgado-Loza JL.Renal globotriaosylceramide deposits for Fabry disease linked to uncertain pathogenicity gene variant c.352C>T/p.Arg118Cys: a family study.Mol Genet Genom Med2019;7:e981 PMCID:PMC6825844

[41] Lenders M,Kurschat C.Alpha-galactosidase A p.A143T, a non-Fabry disease-causing variant.Orphanet J Rare Dis2016;11:54 PMCID:PMC4855861

[42] Terryn W,Hemelsoet D.Questioning the pathogenic role of the GLA p.Ala143Thr “mutation” in Fabry disease: implications for screening studies and ERT. JIMD Reports; Berlin, Heidelberg: Springer; 2012, pp. 102-8.

[43] Nakao S,Takenaka T.Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype.Kidney Int2003;64:801-7

[44] Hasbal NB,Sakaci T.Unexpectedly high prevalence of low alpha-galactosidase a enzyme activity in patients with focal segmental glomerulosclerosis.Clinics2020;75:e1811 PMCID:PMC7510945

[45] Mersher S.Podocyte pathology and nephropathy - sphingolipids in glomerular diseases.Front Endocrinol2014;5:127 PMCID:PMC4115628

[46] Townsend RR,Clawson CM,Li YT.Increased glycosphingolipid excretion associated with proteinuria.J Clin Invest1978;62:119-23 PMCID:PMC371744

[47] West M,Auray-Blais C,Finkle N. Urine Gb3 can be elevated in the absence of Fabry disease: implications for disease screening. In: Canadian Society Nephrology Meeting, St. Johns NL, USA, 27-29 Apr 2012.

[48] Ferraz MJ,Appelman MD.Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases.FEBS Lett2016;590:716-25

[49] Shayman JA.Drug induced phospholipidosis: an acquired lysosomal storage disorder.Biochim Biophys Acta2013;1831:602-11 PMCID:PMC3528828

[50] Choung HYG,Goldman B.Myeloid bodies is not an uncommon ultrastructural finding.Ultrastruct Pathol2022;46:130-8

[51] Chong PF,Kira R.Mulberries in the urine: a tell-tale sign of Fabry disease.J Inherit Metab Dis2018;41:745-6

[52] Zhou LN,Zhang SZ,Huang W.Concurrent Fabry disease and immunoglobulin a nephropathy: a case report.BMC Nephrol2023;24:324 PMCID:PMC10621085

[53] Debiec H,Boyer O.Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy.J Am Soc Nephrol2014;25:675-80 PMCID:PMC3968491

[54] Hunley TE,Dudek M.Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.Pediatrics2004;114:e532-5

[55] Linares D,Loayza E,Ramaswami U.Prevalence of Fabry disease in patients with chronic kidney disease: a systematic review and meta-analysis.Mol Genet Metab2023;140:107714

[56] Schiffmann R,Linthorst GE.Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney disease: improving global outcomes” (KDIGO) controversies conference.Kidney Int2017;91:284-93

[57] Moiseev S,Moiseev A.The benefits of family screening in rare diseases: genetic testing reveals 165 new cases of Fabry disease among at-risk family members of 83 index patients.Genes2022;13:1619 PMCID:PMC9498688

[58] Connaughton DM,Shril S.Monogenic causes of chronic kidney disease in adults.Kidney Int2019;95:914-28 PMCID:PMC6431580

[59] Groopman EE,Cameron-Christie S.Diagnostic utility of exome sequencing for kidney disease.N Engl J Med2019;380:142-51

[60] Jefferies JL,Lau HA.A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm.Orphanet J Rare Dis2021;16:518 PMCID:PMC8686369

[61] Rozenfeld P.Contribution of inflammatory pathways to Fabry disease pathogenesis.Mol Genet Metab2017;122:19-27

[62] Chévrier M,Céline L.Autophagosome maturation is impaired in Fabry disease.Autophagy2010;6:589-99

[63] Bertoldi G,Driussi G.Biochemical mechanisms beyond glycosphingolipid accumulation in Fabry disease: might they provide additional therapeutic treatments?.J Clin Med2023;12:2063 PMCID:PMC10004377

[64] Aerts JM,Kuiper S.Elevated globotriaosylsphingosine is a hallmark of Fabry disease.Proc Natl Acad Sci USA2008;105:2812-7 PMCID:PMC2268542

[65] Sanchez-Niño MD,Carrasco S.Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy.Nephrol Dial Transplant2011;26:1797-802

[66] Eijk M, Ferraz MJ, Boot RG, Aerts JMFG. Lyso-glycosphingolipids: presence and consequences.Essays Biochem2020;64:565-78 PMCID:PMC7517347

[67] Nikolaenko V,Mills K.Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease.Hum Mol Genet2023;32:2464-72 PMCID:PMC10360391

[68] van der Veen SJ,Hollak CEM.Early risk stratification for natural disease course in Fabry patients using plasma globotriaosylsphingosine levels.Clin J Am Soc Nephrol2023;18:1272-82 PMCID:PMC10578638

[69] Alroy J,Kopp JB.Renal pathology in Fabry disease.J Am Soc Nephrol2002;13 Suppl 2:S134-8

[70] Rozenfeld PA,Quieto P.Pathogenesis of Fabry nephropathy: the pathways leading to fibrosis.Mol Genet Metab2020;129:132-41

[71] Wanner C,Ortiz A.Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry registry.Clin J Am Soc Nephrol2010;5:2220-8 PMCID:PMC2994083

[72] Germain DP,Banikazemi M.Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.J Am Soc Nephrol2007;18:1547-57

[73] Najafian B,Bostad L.Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease.Kidney Int2011;79:663-70 PMCID:PMC3640823

[74] Najafian B,Svarstad E,Oliveira JP.Accumulation of globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss.J Am Soc Nephrol2020;31:865-75 PMCID:PMC7191924

[75] Najafian B,Sokolovskiy A.A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease.Kidney Int2022;102:173-82 PMCID:PMC9233139

[76] Braun F,Sellung D.Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy.J Clin Invest2023;133

[77] Schiffmann R.Investigating Fabry disease - some lessons learned.Rare Dis Orphan Drugs J2024;3:4

[78] Jennette, JC, D’Agati, VD. Heptinstall’s pathology of the kidney, 7th ed. Philadelphia: Lippincott Williams and Wilkins; 2014. pp 1232-4.

[79] Colvin RB. Fabry disease. In: Colvin RB, Chang A, editors. Diagnostic pathology: kidney diseases, 3rd ed. Philadelphia: Elsevier; 2019. pp. 400-1.

[80] Gubler MC,Grünfeld JP,Droz D.Early renal changes in hemizygous and heterozygous patients with Fabry’s disease.Kidney Int1978;13:223-35

[81] Svarstad E,Skrunes R,Eikrem Ø.Bedside stereomicroscopy of Fabry kidney biopsies: an easily available method for diagnosis and assessment of sphingolipid deposits.Nephron2018;138:13-21

[82] Colpart P.Fabry nephropathy.Arch Pathol Lab Med2017;141:1127-31

[83] Elleder M,Kozich V.[Fetal pathology in Fabry's disease and mucopolysaccharidosis type I].Cesk Patol1998;34:7-12

[84] Reasor MJ,Ulrich RG.Drug-induced phospholipidosis: issues and future directions.Expert Opin Drug Saf2006;5:567-83

[85] Grafft CA,Semret MH,Sethi S.Renal involvement in neimann-pick disease.NDT Plus2009;2:448-51 PMCID:PMC4421332

[86] Banks DE,Desnick RJ,Lapp NL.Silicon nephropathy mimicking Fabry’s disease.Am J Nephrol1983;3:279-84

[87] Lei L,Sutherland S.Myelin bodies in LMX1B-associated nephropathy: potential for misdiagnosis.Pediatr Nephrol2020;35:1647-57

[88] Hirashio S,Naito T.Characteristic kidney pathology, gene abnormality and treatments in LCAT deficiency.Clin Exp Nephrol2014;18:189-93

[89] Ni HF,Li CQ,Liu BC.Myeloid bodies caused by COQ2 mutation: a case of concurrent COQ2 nephropathy and IgA nephropathy.Clin Kidney J2021;14:1697-700 PMCID:PMC8162858

[90] Su H,Wen Q,Yi LX.Case report: lipid inclusion in glomerular endothelial and mesangial cells in a patient after contrast medium injection.BMC Nephrol2018;19:53 PMCID:PMC5840718

[91] Hull MT.Myelinoid lamellated cytoplasmic inclusions in human renal adenocarcinomas: an ultrastructural study.Ultrastruct Pathol1988;12:41-8

[92] Kadosawa K,Konishi Y.Zebra bodies without Fabry disease or hydroxychloroquine.Clin Exp Nephrol2021;25:94-6

[93] Tøndel C,Larsen KK.Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.Nephron2015;129:16-21

[94] Tøndel C,Hirth A.Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria.Am J Kidney Dis2008;51:767-76

[95] Valbuena C,Carneiro F.Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections.Virchows Arch2012;460:211-21

[96] Mauer M,Svarstad E.Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease.PLoS One2014;9:e112188 PMCID:PMC4227696

[97] Fogo AB,Svarstad E.Scoring system for renal pathology in Fabry disease: report of the international study group of fabry nephropathy (ISGFN).Nephrol Dial Transplant2010;25:2168-77 PMCID:PMC2902894

[98] Müller-Höcker J,Weiss M,Braun GS.Chloroquine-induced phospholipidosis of the kidney mimicking Fabry’s disease: case report and review of the literature.Hum Pathol2003;34:285-9

[99] Renwick N,Chung WK.Foamy podocytes.Am J Kidney Dis2003;41:891-6

[100] Chen TK,Grams ME.Chronic kidney disease diagnosis and management: a review.JAMA2019;322:1294-304 PMCID:PMC7015670

[101] Francini-Pesenti F,Bertoldi G,Calò LA.Could nutritional therapy take us further in our approaches to Fabry disease?.Nutrition2020;72:110664

[102] Mroczek M,Sendel M,Seifritz E.Neuropsychiatric symptoms and their association with sex, age, and enzyme replacement therapy in Fabry disease: a systematic review.Front Psychiatry2022;13:829128 PMCID:PMC8967288

[103] Tahir H,Warnock DG.Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.J Am Soc Nephrol2007;18:2609-17

[104] Warnock DG,Vujkovac B.Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.J Med Genet2015;52:860-6 PMCID:PMC4717450

[105] Epstein M,Clase CM,Pecoits-Filho R.Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms.Am J Kidney Dis2022;80:658-66

[106] Trujillo H,Caro J,Praga M.The forgotten antiproteinuric properties of diuretics.Am J Nephrol2021;52:435-49

[107] Unruh ML,Demko JE,Hughey RP.Trial of amiloride in type 2 diabetes with proteinuria.Kidney Int Rep2017;2:893-904 PMCID:PMC5584552

[108] Trimarchi H,Lombi F.Amiloride as an alternate adjuvant antiproteinuric agent in Fabry disease: the potential roles of plasmin and uPAR.Case Rep Nephrol2014;2014:854521 PMCID:PMC4052478

[109] Heerspink HJL,Correa-Rotter R.Dapagliflozin in patients with chronic kidney disease.N Engl J Med2020;383:1436-46

[110] Packer M,Zannad F.Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial.Circulation2021;144:1284-94

[111] Bothou C,Nowak A.Endocrine disorders in patients with Fabry disease: insights from a reference centre prospective study.Endocrine2022;75:728-39 PMCID:PMC8888367

[112] Pisani A,Duro G,Riccio E.Antiproteinuric effect of add-on paricalcitol in Fabry disease patients: a prospective observational study.Nephrol Dial Transplant2015;30:661-6

[113] Keber T,Cokan Vujkovac A,Ravber K.Paricalcitol as an antiproteinuric agent can result in the deterioration of renal and heart function in a patient with Fabry disease.Am J Case Rep2017;18:644-8 PMCID:PMC5471926

[114] Larsen T,Bech JN.Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial.BMC Nephrol2013;14:163 PMCID:PMC3729723

[115] Humalda JK,Thadhani R.Vitamin D analogues to target residual proteinuria: potential impact on cardiorenal outcomes.Nephrol Dial Transplant2015;30:1988-94 PMCID:PMC4832986

[116] Dincer MT,Ikitimur B.Blood pressure variability in Fabry disease patients.Nephron2022;146:343-50

[117] Kim SH.Management of hypertension in Fabry disease.Electrolyte Blood Press2023;21:8-17 PMCID:PMC10329903

[118] Sims K,Banikazemi M.Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.Stroke2009;40:788-94

[119] Politei JM,Germain DP.Pain in Fabry disease: practical recommendations for diagnosis and treatment.CNS Neurosci Ther2016;22:568-76 PMCID:PMC5071655

[120] Ouyang Y,Zhao Z.Globotriaosylsphingosine improves risk stratification of kidney progression in Fabry disease patients.Clin Chim Acta2024;556:117851

[121] Pastores GM,Crandall K,Piersall L.Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.Nephrol Dial Transplant2007;22:1920-5

[122] Mignani R,Pisani A.Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.Nephrol Dial Transplant2008;23:1628-35

[123] Woolen SA,Gagnier JJ,Singer L.Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis.JAMA Intern Med2020;180:223-30 PMCID:PMC6902198

[124] Capelli I,Gasperoni L.Kidney transplant in Fabry disease: a revision of the literature.Medicina2020;56:284 PMCID:PMC7353860

[125] Odani K,Honda K,Tanabe K.Kidney transplantation from a mother with unrecognized Fabry disease to her son with low α-galactosidase a activity: a 14-year follow-up without enzyme replacement therapy.Nephrology2016;21:57-9

[126] Puliyanda DP,Bunnapradist S,Jordan SC.Fabry disease in a renal allograft.Am J Transplant2003;3:1030-2

[127] Mignani R,Giudicissi A.Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.Kidney Int2004;65:1381-5

[128] Naseer MS,Coppola S,Sharma M.Post-transplant de-novo renal phospholipidosis in a kidney transplant recipient: Fabry disease or something else?.Clin Nephrol Case Stud2020;8:46-8 PMCID:PMC7303541

[129] Fujii H,Hara S,Nishi S.Histological changes of a kidney in a recipient who received an allograft from a patient with Fabry disease.J Nephrol2020;33:657-9

[130] Aasebø W,Hovig T,Heiberg A.Fabry disease in donor kidneys with 3- and 12-year follow-up after transplantation.NDT Plus2010;3:303-5 PMCID:PMC5477959

[131] Zarate YA,Yin H.A case of minimal change disease in a Fabry patient.Pediatr Nephrol2010;25:553-6

[132] Lenders M,Nowak A.Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease.J Intern Med2017;282:241-53

[133] ^PrFABRAZYME®. Available from: https://pdf.hres.ca/dpd_pm/00075174.PDF [Last accessed on 11 Jul 2024].

[134] ^PrREPLAGA®. Available from: https://pdf.hres.ca/dpd_pm/00063277.PDF [Last accessed on 11 Jul 2024].

[135] ^PrGALAFOLD®. Available from: https://pdf.hres.ca/dpd_pm/00071852.PDF [Last accessed on 11 Jul 2024].

[136] Benjamin ER,Wu X.The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.Genet Med2017;19:430-8 PMCID:PMC5392595

[137] Eng CM,Wilcox WR.Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry’s disease.N Engl J Med2001;345:9-16

[138] Schiffmann R,Austin HA 3rd.Enzyme replacement therapy in Fabry disease: a randomized controlled trial.JAMA2001;285:2743-9

[139] Eng CM,Gordon RE.A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.Am J Hum Genet2001;68:711-22

[140] Thurberg BL,Colvin RB.Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.Kidney Int2002;62:1933-46

[141] Banikazemi M,Waldek S.Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.Ann Intern Med2007;146:77-86

[142] Germain DP,Desnick RJ.Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.J Med Genet2015;52:353-8 PMCID:PMC4413801

[143] Cybulla M,Feriozzi S.Renoprotective effect of agalsidase alfa: a long-term follow-up of patients with Fabry disease.J Clin Med2022;11:4810 PMCID:PMC9410255

[144] Najafian B,Svarstad E,Smith K.One year of enzyme replacement therapy reduces globotriaosylceramide inclusions in podocytes in male adult patients with Fabry disease.PLoS One2016;11:e0152812 PMCID:PMC4833322

[145] Mauer M,Barth JA.Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment.J Med Genet2017;54:781-6 PMCID:PMC5740534

[146] Tøndel C,Larsen KK.Agalsidase benefits renal histology in young patients with Fabry disease.J Am Soc Nephrol2013;24:137-48 PMCID:PMC3537211

[147] Ramaswami U,Clarke LA.Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: a 5-year randomized controlled trial.Mol Genet Metab2019;127:86-94

[148] Hughes DA,Shankar SP.Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.J Med Genet2017;54:288-96 PMCID:PMC5502308

[149] Bichet DG,Wallace E.Long-term follow-up of renal function in patients treated with migalastat for Fabry disease.Mol Genet Metab Rep2021;28:100786

[150] Nowak A,Krayenbuehl PA,Schiffmann R.Fabry disease genotype, phenotype, and migalastat amenability: insights from a national cohort.J Inherit Metab Dis2020;43:326-33

[151] Hughes D,Jovanovic A.FollowME Fabry pathfinders registry: renal effectiveness in a multi-national, multi-center cohort of patients on migalastat treatment for at least three years.Mol Genet Metab2023;138:107159

[152] Lenders M,Kurschat C.Treatment of Fabry's disease with migalastat: outcome from a prospective observational multicenter study (FAMOUS).Clin Pharmacol Ther2020;108:326-37

[153] West ML,Iwanochko R,Sirrs S.Initiation of pharmacologic chaperone therapy for Fabry disease in the Canadian Fabry disease initiative (CFDI) registry is not associated with reduction of kidney function.Mol Genet Metab2024;141:108079

[154] West ML,Sandila N.Switch from enzyme replacement therapy to pharmacologic chaperone: improvement in advanced Fabry nephropathy.Mol Genet Metab2024;141:108077

[155] Biegstraaten M,Barbey F.Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.Orphanet J Rare Dis2015;10:36 PMCID:PMC4383065

[156] Hughes D,Gurevich A,Jazukeviciene D.FOS Study GroupPrompt agalsidase alfa therapy initiation is associated with improved renal and cardiovascular outcomes in a Fabry outcome survey analysis.Drug Des Devel Ther2021;15:3561-72 PMCID:PMC8379390

[157] van der Veen SJ,Hirsch A.Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression.Mol Genet Metab2022;135:163-9

[158] Schiffmann R,Blankenship D.Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.Genet Med2013;15:983-9

[159] Talbot A,Fletcher JM.A simple method for quantification of plasma globotriaosylsphingosine: utility for Fabry disease.Mol Genet Metab2017;122:121-5

[160] Bichet DG,Auray-Blais C.Assessment of plasma lyso-Gb₃ for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease.Genet Med2021;23:192-201 PMCID:PMC7790748

[161] Germain DP,Nicholls K.Treatment of Fabry’s disease with the pharmacologic chaperone migalastat.N Engl J Med2016;375:545-55

[162] Lenders M,Niemietz C.Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy.J Med Genet2019;56:548-56

[163] Rombach SM,Poorthuis BJHM.Long-term effect of antibodies against infused alpha-galactosidase a in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.PLoS One2012;7:e47805 PMCID:PMC3477102

[164] Germain DP,Hughes DA.Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase a activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies.Orphanet J Rare Dis2012;7:91 PMCID:PMC3527132

[165] Hughes DA,Giugliani R.Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes.J Med Genet2023;60:722-31 PMCID:PMC10359570

[166] Schiffmann R,Holida M.Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year phase 1/2 clinical trial.J Inherit Metab Dis2019;42:534-44

[167] Linhart A,Nicholls K.Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study.Orphanet J Rare Dis2023;18:332 PMCID:PMC10589982

[168] Wallace EL,Wilcox WR.Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.J Med Genet2024;61:520-30 PMCID:PMC11137442

[169] Deegan PB.Fabry disease, enzyme replacement therapy and the significance of antibody responses.J Inherit Metab Dis2012;35:227-43

[170] Bodensteiner D,Sims KB,Cintron RD.Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme.Genet Med2008;10:353-8

[171] Talreja N,Del Valle RL,Lockey RF.Successful desensitization to agalsidase beta after anaphylaxis.Ann Allergy Asthma Immunol2014;112:71-2

[172] Linthorst GE,Donker-Koopman WE,Aerts JM.Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.Kidney Int2004;66:1589-95

[173] Lenders M,Rudnicki M.Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease.J Am Soc Nephrol2018;29:2879-89 PMCID:PMC6287863

[174] van der Veen SJ,van Dussen L.Predicting the development of anti-drug antibodies against recombinant alpha-galactosidase a in male patients with classical Fabry disease.Int J Mol Sci2020;21:5784 PMCID:PMC7460974

[175] Lenders M.Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease.Front Immunol2022;13:1024963 PMCID:PMC9782970

[176] Curelaru S,Fink D,Kishnani PS.A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation.Mol Genet Metab Rep2022;32:100893 PMCID:PMC9263520

[177] Mhanni AA,Boutin M.Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres.Mol Genet Metab Rep2020;24:100618 PMCID:PMC7322173

[178] Hughes D,Maegawa G.Long-term safety and efficacy of pegunigalsidase alfa: a multicenter 6-year study in adult patients with Fabry disease.Genet Med2023;25:100968

[179] FDA. 2023. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761161s000lbl.pdf [Last accessed on 11 Jul 2024].

[180] Lenders M,Terlinden M.Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa.Mol Ther Methods Clin Dev2022;26:323-30 PMCID:PMC9379515

[181] Guérard N,Nordbeck P.Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement.Clin Pharmacol Ther2018;103:703-11

[182] Deegan PB,Geberhiwot T.Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study.Mol Genet Metab2023;138:106963 PMCID:PMC9918698

[183] Khan A,Huang J.Lentivirus-mediated gene therapy for Fabry disease.Nat Commun2021;12:1178 PMCID:PMC7907075

[184] Hopkin RJ,Bernat J.Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: updated results from an ongoing phase 1/2 study (STAAR).Mol Genet Metab2024;141:107884

[185] Schiffmann R,Vockley J.Cardiac effects of 4D-310 in adults with Fabry disease in a phase 1/2 clinical trial: Functional, quality of life, and imaging endpoints in patients with 12 months of follow up.Mol Genet Metab2023;138:107306

[186] Lek A,Keeler A.Death after high-dose rAAV9 gene therapy in a patient with Duchenne’s muscular dystrophy.N Engl J Med2023;389:1203-10

[187] Nagree MS,Faber ML.Autologous, lentivirus-modified, T-rapa cell “micropharmacies” for lysosomal storage disorders.EMBO Mol Med2022;14:e14297 PMCID:PMC8988206

[188] Romano R,Pios A,Selby MJ.Development of a B cell protein factory to produce sustained therapeutic levels of alpha-galactosidase a for the treatment of Fabry disease.Mol Genet Metab2023;138:107298

[189] Ter Huurne M,Liu NQ.GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals.Am J Hum Genet2023;110:1600-5 PMCID:PMC10502840

[190] Domm JM,Medin JA.Gene therapy for Fabry disease: progress, challenges, and outlooks on gene-editing.Mol Genet Metab2021;134:117-31

[191] Takahashi H,Migita M.Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.Proc Natl Acad Sci USA2002;99:13777-82 PMCID:PMC129774